CEL-SCI Co. (CVM) Rating Reiterated by Dawson James

Dawson James reaffirmed their neutral rating on shares of CEL-SCI Co. (NYSEMKT:CVM) in a research note issued to investors on Monday.

Separately, ValuEngine raised shares of CEL-SCI from a strong sell rating to a sell rating in a research note on Monday, August 14th.

Shares of CEL-SCI (CVM) opened at 1.80 on Monday. The company has a 50 day moving average of $1.72 and a 200-day moving average of $1.31. CEL-SCI has a 12-month low of $0.06 and a 12-month high of $3.69. The firm’s market cap is $16.80 million.

COPYRIGHT VIOLATION WARNING: “CEL-SCI Co. (CVM) Rating Reiterated by Dawson James” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/10/20/cel-sci-co-cvm-rating-reiterated-by-dawson-james.html.

In other CEL-SCI news, insider Eyal Talor sold 14,019 shares of CEL-SCI stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $2.61, for a total value of $36,589.59. Following the completion of the transaction, the insider now directly owns 131,312 shares of the company’s stock, valued at $342,724.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

CEL-SCI Company Profile

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.

Receive News & Ratings for CEL-SCI Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply